Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Role of Measurable Residual Disease (MRD) in Redefining Complete Response (CR) in Elderly Patients with Acute Myeloid Leukemia (AML): Results from the Pethema-Flugaza Phase III Clinical Trial

Blood (2018) 132 (Supplement 1): 433.

https://doi.org/10.1182/blood-2018-99-113299

Published: 2018

Journal Articles

Similar Probabilities of Failure to Reach Transplantation and Transplant Outcomes after HLA-Identical Sibling or Unrelated Donor Transplant in Patients with Acute Myeloid Leukemia: A Single Institution Evaluation of a Donor Selection Algorithm

Eduardo Rodríguez-Arbolí, MD, Francisco J. Márquez-Malaver, RN, Nancy Rodríguez-Torres, MD, Teresa Caballero-Velázquez, MD PhD, Virginia Escamilla Gomez, Cristina Calderón-Cabrera, MD, José F. Falantes, MD, Ildefonso Espigado, MD PhD, José A. Pérez-Simón

Blood (2017) 130 (Supplement 1): 5548.

https://doi.org/10.1182/blood.V130.Suppl_1.5548.5548

Published: 2017

Journal Articles

Multivariable Time-Dependent Analysis Of The Impact Of 5 Azacitidine In Patients With Lower-Risk Myelodysplastic Syndrome and Unfavorable Specific Lower-Risk Score

Blood (2013) 122 (21): 2754.

https://doi.org/10.1182/blood.V122.21.2754.2754

Published: 2013

Journal Articles

The Presence Of 1 / 8 HLA Mismatch Do Not Hamper Survival After Allogeneic Stem Cell Transplantation Using Immunoprophylaxis With Sirolimus-Tacrolimus

Rocío Parody, MD, PhD, Lucía López-Corral, MD, PhD, Oriana Lopez Godino, MD, Irene García Cadenas, Vazquez Lourdes, MD, Rodrigo Martino, MD, PhD, Carmen Martinez, Carlos Solano, Ariadna Perez Martinez, Pere Barba, MD, David Valcarcel, MD, Jose F. Falantes, MD, Francisco J Márquez-Malaver, Dolores Caballero, MD, PhD, Jose Antonio Perez-Simón, MD, PhD

Blood (2013) 122 (21): 4529.

https://doi.org/10.1182/blood.V122.21.4529.4529

Published: 2013

Journal Articles

Azacitidine Alone Or The Combination With Valproic Acid As a Bridge Therapy For Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes Before Transplantation

Cristina Calderón Cabrera, Jose F Falantes, MD, Marina Gómez, Rocío Parody, MD, PhD, Francisco J Márquez Malaver, María L Martino, José González, Isabel Montero, Ildefonso Espigado, Jose Antonio Pérez-Simón

Blood (2013) 122 (21): 2812.

https://doi.org/10.1182/blood.V122.21.2812.2812

Published: 2013

Journal Articles

Multivariate Analysis of the Impact of Pre-Treatment Serum Ferritin Level On Response and Overall Survival in Patients with Myelodysplastic Syndromes Treated with Azacitidine

Regina Garcia Delgado, Dunia de Miguel, Alicia Bailen, José Ramón Gonzalez, Joan Bargay, Jose F Falantes, MD, Rafael Andreu, Fernando Ramos, Mar Tormo, Rafael F Duarte, MD, PhD, Ma José Jiménez Lorenzo, Salut Brunet, Benet Nomdedeu, Antonio Figueredo, Javier Casaño, Llorenç Badiella, Antonio Fernández Jurado, Guillermo Sanz

Blood (2012) 120 (21): 1710.

https://doi.org/10.1182/blood.V120.21.1710.1710

Published: 2012

Journal Articles

Increased Gene Expression Involved in Angiogenesis, Metabolism and Cell Proliferation in Acute Myeloid Leukemia and myelodysplastic Syndromes Correlates with Adverse Clinical and Biological Features

Jose F Falantes, MD, Pablo Trujillo, Cristina Calderón, MD, Jose Gonzalez, MD, Maria Luz Martino, Isabel Montero, MD, Rocio Parody, MD, Ildefonso Espigado, MD, PhD, Jose Antonio Perez-Simón

Blood (2012) 120 (21): 1457.

https://doi.org/10.1182/blood.V120.21.1457.1457

Published: 2012

Journal Articles

Patterns of Infection in Patients with Myeloid Malignancies Receiving 5-Azacytidine: identification of Candidates for Antifungal Prophylaxis

Cristina Calderón, MD, Jose F Falantes, MD, Francisco Márquez-Malaver, MD, Jose González, MD, PhD, Maria Luz Martino, MD, Isabel Montero, MD, Ildefonso Espigado, MD, PhD, Jose Antonio Pérez-Simón, MD, PhD

Blood (2012) 120 (21): 4955.

https://doi.org/10.1182/blood.V120.21.4955.4955

Published: 2012

Journal Articles

Prognostic Factors for Survival and Progression to Acute Myeloid Leukemia in Patients with Lower-Risk Myelodysplastic Syndromes. A New Scoring System

Jose F Falantes, MD, Cristina Calderón, MD, Ildefonso Espigado, MD, PhD, Dora Alonso, MD, Antonio Martín Noya, MD, PhD, Estrella Carrillo, MD, Maria Luz Martino, MD, Isabel Montero, MD, Jose González, MD, PhD, Jose Antonio Pérez-Simón, MD, PhD

Blood (2011) 118 (21): 1730.

https://doi.org/10.1182/blood.V118.21.1730.1730

Published: 2011

Journal Articles

Differential Gene Expression Involved In Angiogenesis, Metabolism, Cell Proliferation and Self-Renewal and Pluripotency In Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

Jose F Falantes, MD, Cristina Calderón, MD, Pablo Trujillo, Beatriz Martin-Antonio, Jose González, MD, PhD, Alvaro Urbano, MD, Magdalena Carmona, MD, Ildefonso Espigado, MD, PhD

Blood (2010) 116 (21): 4646.

https://doi.org/10.1182/blood.V116.21.4646.4646

Published: 2010

Journal Articles

Azacitidine Is Effective in Patients with Intermediate-2 / High IPSS Risk Myelodysplastic Syndrome Managed in Community Based Practice: Preliminary Data From the Spanish Azacitidine Compassionate Use Registry.

Regina Garcia, MD, José Ramón González, MD, PhD, Alicia Bailen, MD, Jose F Falantes, MD, Joaquin Sanchez, MD, Rafael F Duarte, Juan Besalduch, MD, Andreu Lapiedra, MD

Blood (2009) 114 (22): 4835.

https://doi.org/10.1182/blood.V114.22.4835.4835

Published: 2009

Journal Articles

Azacitidine Is Effective in Patients with Myelodysplastic Syndrome Managed in Community-Based Practice: Preliminary Data From the Spanish Azacitidine Compassionate Use Registry.

Regina Garcia, MD, Dunia de Miguel, MD, Alicia Bailen, MD, Jose Ramon Gonzalez, MD, PhD, Rafael Andreu, MD, Mar Tormo, MD, Jose F Falantes, MD, Guillermo Sanz, Rafael F Duarte, Antonio Figueredo, MD

Blood (2009) 114 (22): 4836.

https://doi.org/10.1182/blood.V114.22.4836.4836

Published: 2009

Journal Articles

Effectiveness and Tolerance of Azacitidine for Treating Patients with Chronic Myelomonocytic Leukemia in Community-Based Management.

Regina Garcia, MD, Maria E Amutio, MD, Manuel Almagro, MD, Alicia Bailen, MD, Jose F Falantes, MD, Marta Garcia, MD, Angela Ibañez, MD, Reyes Sanchotello, MD, Guillermo Sanz

Blood (2009) 114 (22): 4855.

https://doi.org/10.1182/blood.V114.22.4855.4855

Published: 2009

Journal Articles

Different Clinical Results with the Use of Different Dosing Schedules of Azacitidine in Patients with Myelodysplastic Syndrome Managed in Community-Based Practice: Effectiveness and Safety Data From the Spanish Azacitidine Compassionate Use Registry.

Regina Garcia, MD, Dunia de Miguel, MD, Alicia Bailen, MD, José Ramón González, MD, PhD, Guillermo Sanz, Jose F Falantes, MD, Rafael Andreu, MD, Mar Tormo, MD, Rafael F Duarte, Antonio Figueredo, MD

Blood (2009) 114 (22): 2773.

https://doi.org/10.1182/blood.V114.22.2773.2773

Published: 2009

Journal Articles

Incidence of Neutropenia and Hypogammaglobulinemia and Correlation with the Infections Rate in Indolent Non-Hodgkin Lymphoma (NHL) Receiving Rituximab Maintenance.

Ana Marin-Niebla, MD, Eduardo Rios-Herranz, MD, Jose F. Falantes, MD, Mariluz Martino, MD, Ildefonso Espigado, MD PhD, Alvaro Urbano-Ispizua, MD PhD

Blood (2007) 110 (11): 4495.

https://doi.org/10.1182/blood.V110.11.4495.4495

Published: 2007

NARROW

Role of Measurable Residual Disease (MRD) in Redefining Complete Response (CR) in Elderly Patients with Acute Myeloid Leukemia (AML): Results from the Pethema-Flugaza Phase III Clinical Trial

Similar Probabilities of Failure to Reach Transplantation and Transplant Outcomes after HLA-Identical Sibling or Unrelated Donor Transplant in Patients with Acute Myeloid Leukemia: A Single Institution Evaluation of a Donor Selection Algorithm

Multivariable Time-Dependent Analysis Of The Impact Of 5 Azacitidine In Patients With Lower-Risk Myelodysplastic Syndrome and Unfavorable Specific Lower-Risk Score

The Presence Of 1 / 8 HLA Mismatch Do Not Hamper Survival After Allogeneic Stem Cell Transplantation Using Immunoprophylaxis With Sirolimus-Tacrolimus

Azacitidine Alone Or The Combination With Valproic Acid As a Bridge Therapy For Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes Before Transplantation

Multivariate Analysis of the Impact of Pre-Treatment Serum Ferritin Level On Response and Overall Survival in Patients with Myelodysplastic Syndromes Treated with Azacitidine

Increased Gene Expression Involved in Angiogenesis, Metabolism and Cell Proliferation in Acute Myeloid Leukemia and myelodysplastic Syndromes Correlates with Adverse Clinical and Biological Features

Patterns of Infection in Patients with Myeloid Malignancies Receiving 5-Azacytidine: identification of Candidates for Antifungal Prophylaxis

Prognostic Factors for Survival and Progression to Acute Myeloid Leukemia in Patients with Lower-Risk Myelodysplastic Syndromes. A New Scoring System

Differential Gene Expression Involved In Angiogenesis, Metabolism, Cell Proliferation and Self-Renewal and Pluripotency In Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

Azacitidine Is Effective in Patients with Intermediate-2 / High IPSS Risk Myelodysplastic Syndrome Managed in Community Based Practice: Preliminary Data From the Spanish Azacitidine Compassionate Use Registry.

Azacitidine Is Effective in Patients with Myelodysplastic Syndrome Managed in Community-Based Practice: Preliminary Data From the Spanish Azacitidine Compassionate Use Registry.

Effectiveness and Tolerance of Azacitidine for Treating Patients with Chronic Myelomonocytic Leukemia in Community-Based Management.

Different Clinical Results with the Use of Different Dosing Schedules of Azacitidine in Patients with Myelodysplastic Syndrome Managed in Community-Based Practice: Effectiveness and Safety Data From the Spanish Azacitidine Compassionate Use Registry.

Incidence of Neutropenia and Hypogammaglobulinemia and Correlation with the Infections Rate in Indolent Non-Hodgkin Lymphoma (NHL) Receiving Rituximab Maintenance.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only